Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/28726234
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
[Current status of congenital myasthenic syndromes].
[Article in Spanish; Abstract available in Spanish from the publisher]
Bestue-Cardiel M1, Natera-de Benito D2.
Rev Neurol. 2017 Aug 16;65(4):161-176.
Since Engel reported the first case of congenital myasthenia in 1977 and the first pathogenic gene was found in 1995, knowledge about congenital myasthenic syndromes has continued to grow.
Over the years, the pathogenic basis, its clinical features, the phenotype-genotype correlations that have been established and its therapeutic management have all been described.
In this group of diseases the safety margin of neuromuscular transmission is altered by different mechanisms: in the synthesis or storage of acetylcholine quanta in the synaptic vesicles, in the calcium-mediated release of acetylcholine in the nerve terminal or in the efficiency of the quantum released to generate a post-synaptic depolarisation.
Increased knowledge about them has enabled a number of different therapeutic strategies to be established.
In this review the main updates on these syndromes are reported, including: the genes described as classifying 50% of cases, their current classification based on the localisation of the proteins that alter neuromuscular transmission, including a new group of congenital myasthenias, glycosylation disorders, the main key diagnoses and the therapeutic management of this group of under-diagnosed patient.